Forte Biosciences (FBRX) Stock Price, News & Analysis

Company Overview

Forte Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis. FB-401 has shown promise in early studies for reducing inflammation and improving barrier function, and is currently being evaluated in Phase 2 clinical trials. In addition to atopic dermatitis, Forte is exploring pipeline opportunities in rare genetic skin conditions such as epidermolysis bullosa, where reinforcing the skin’s protective barrier is a critical unmet need.

Forte Biosciences conducts clinical research across North America and Europe, collaborating with academic institutions and patient advocacy groups to accelerate development timelines. The company’s management team comprises professionals with extensive experience in biotechnology R&D, regulatory affairs, and commercial strategy, positioning Forte to translate scientific discoveries into potential therapeutic options for patients with chronic and rare skin disorders.

Key Stats

• Today's Range: $14.39 to $15.50
• 50-Day Range: $9.70 to $15.86
• 52-Week Range: $4.11 to $28.68
• Volume: 66,679 shs
• Average Volume: 107,994 shs
• Market Capitalization: $183.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $68.00
• Consensus Rating: Moderate Buy

Forte Biosciences Stock Analysis - MarketRank™

Forte Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 533rd out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Forte Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Forte Biosciences has a consensus price target of $68.00, representing about 361.0% upside from its current price of $14.75.

Amount of Analyst Coverage

Forte Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Forte Biosciences are expected to grow in the coming year, from ($12.12) to ($3.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Forte Biosciences is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Forte Biosciences is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Forte Biosciences has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.06% of the float of Forte Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Forte Biosciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Forte Biosciences has recently increased by 14.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Forte Biosciences does not currently pay a dividend.

Dividend Growth

Forte Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.06% of the float of Forte Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Forte Biosciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Forte Biosciences has recently increased by 14.05%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.83

News Sentiment

Forte Biosciences has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Forte Biosciences this week, compared to 1 article on an average week.

Search Interest

Only 5 people have searched for FBRX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Forte Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.90% of the stock of Forte Biosciences is held by insiders.

Percentage Held by Institutions

77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FBRX Stock Analysis - Frequently Asked Questions

How have FBRX shares performed this year?

Forte Biosciences' stock was trading at $22.71 at the beginning of 2025. Since then, FBRX stock has decreased by 35.1% and is now trading at $14.75.

How were Forte Biosciences' earnings last quarter?

Forte Biosciences, Inc. (NASDAQ:FBRX) posted its earnings results on Thursday, August, 14th. The company reported ($0.96) EPS for the quarter, topping analysts' consensus estimates of ($1.21) by $0.25.

How do I buy shares of Forte Biosciences?

Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Forte Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Forte Biosciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), PayPal (PYPL), QUALCOMM (QCOM), Avino Silver & Gold Mines (ASM), Meta Platforms (META) and Zoom Communications (ZM).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/13/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FBRX
• CIK: 1419041
• Web: www.fortebiorx.com
• Phone: (310) 618-6994
• Fax: N/A
• Employees: 5
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Forte Biosciences: $68.00
• High Price Target: $75.00
• Low Price Target: $61.00
• Potential Upside/Downside: +364.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($16.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.48 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -85.38%
• Return on Assets: -72.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.74
• Quick Ratio: 11.74

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.21 per share
• Price / Book: 1.78

Miscellaneous

• Outstanding Shares: 12,433,000
• Free Float: 11,699,000
• Market Cap: $182.02 million
• Optionable: Optionable
• Beta: 3.03